Strategic Commitment 4
Delivering real value from healthcare innovation
The InnoScot Health product and spin-out portfolio presents a record of successful health outcomes. Developed in collaboration with health professionals, a range of medical devices, products and technologies are in use internationally across hospitals, care homes and on-scene emergency settings.
Whilst healthcare innovations must deliver benefit to the NHS and its patient population; to deliver a truly holistic view we must focus not just on health, but social and economic benefits too. Successful healthcare innovations have the potential to create jobs, attract further investment to Scotland and strengthen our innovation profile on the international stage. We must spotlight the broader significance, and benefits, of health innovation within the wider entrepreneurial vision for Scotland, promoting the benefits of successfully commercialised and sustainable health innovations.
To achieve this, InnoScot Health has placed a focus not just on health, but social and economic benefits of healthcare innovation. By generating an income stream to NHS Boards through financial returns on co-development projects we can support reinvestment in further innovation. Communicating success stories to the media also helps strengthen Scotland’s innovation profile and spotlights the significance, and benefits, of health innovation within the wider entrepreneurial vision for Scotland.
Economic Benefits, Generating Income
To support successful commercialisation, InnoScot Health has a robust evaluation process for all new disclosures. This includes a tool for economic analysis of innovations, helping to determine the potential value of innovations before they enter costly and time-intensive development.
Developed and implemented during Summer 2022, the health economic analysis tool now forms part of the evaluation process for disclosures submitted to InnoScot Health. By incorporating economic principles early in the research and development process, InnoScot Health can determine the economic viability of projects, and work with stakeholders to prioritise resources efficiently and align preclinical efforts with broader healthcare goals.
Working closely with licence partners and NHS spinouts post commercialisation, InnoScot Health helps to grow sales, reach new markets and optimise value. This helps to grow an income stream to NHS health boards through financial returns on co-development projects.
Commercialisation is our end goal and a crucial step, generating revenue for the innovator, but also the employing health board. This helps NHS Scotland to reinvest in further innovation while realising improvements in patient care.
Robert Rea, Head of Innovation, InnoScot Health
Strengthening Scotland's Innovation Profile
Supporting the translation of ideas into viable products and services is central to the work of InnoScot Health, but ongoing support is also provided to licence partners and spinouts. From membership on Boards, to PR support and joint promotional activity, InnoScot Health aims to maximise the profile of NHS-led innovation.
Supporting development of breakthrough stroke technology
A 2015 spinout of InnoScot Health, NHS Greater Glasgow and Clyde, and the University of Glasgow, Aurum Biosciences is a clinical stage biopharmaceuticals company developing novel therapeutics and diagnostics in areas of unmet clinical need. Ongoing PR support ensures new investment and exciting plans to further develop its state-of-the-art therapeutic and diagnostic technology are maximised, with 33 pieces of media coverage between March 2021 and September 2024.
Making patients lives better through the development of innovative solutions
A 2007 spinout company of InnoScot Health, NHS Greater Glasgow and Clyde, and the Golden Jubilee National Hospital, CardioPrecision is a technology company developing medical devices for the treatment of structural heart disease and cardiothoracic interventions.
Their patented CoreVista® Retractor and accessories allow cardiothoracic surgery to be performed through a short incision in the skin crease of the neck.
Ongoing PR support ensures new investment and exciting plans for roll out of the patented CoreVista® technology is maximised, with 38 pieces of media coverage between March 2021 and September 2024.
To ensure continued awareness of NHS innovations and maximise promotional opportunities, InnoScot Health maintains strong relationships with the licence partners of successfully commercialised products.
Openhouse™ Products
As manufacturer and distributor of the portfolio of SCRAM™ products, InnoScot Health has worked in partnership with OpenHouse since 2017. They have a small manufacturing site in Birkenhead which supplies bags for US distribution and a manufacturing partner in the Middle East. Collaboration on marketing and PR activity helps to maximise promotional opportunities and support the expansion of the product line.
Marsden Weighing
As manufacturer and distributor of the Patient Transfer Scale, InnoScot Health has worked in partnership with Marsden since 2016. The Patient Transfer Scale has been adopted across the NHS and sold worldwide. Collaboration on marketing and PR activity helps to demonstrate the potential of NHS-led innovation in both global adoption and award recognition.
Keela
As manufacturer and distributor of the SARUS-CPR hood, InnoScot Health has worked in partnership with Keela since 2021. Collaboration on marketing and PR activity has helped to spotlight the product benefits and raise awareness of published papers on product performance.
Our Contribution to National and Global Priorities
This commitment aligns with Scotland's National Outcomes in the Health, Economy, and Fair Work and Business; International; and Poverty categories.
It aligns with the United Nations Sustainable Development Goals in the No Poverty; Good Health and Wellbeing; Decent Work and Economic Growth; Industry, Innovation and Infrastructure; Reduced Inequalities; Sustainable Cities and Communities; and Partnerships for the Goals categories.
Chat